Bristol-Myers Squibb Co.
Company Snapshot
Company Overview
Bristol Myers Squibb Co. is a global biopharmaceutical company. The drug manufacturing company focuses on cardiovascular, anti-infective, and anticancer therapies. It undertakes the discovery, development, licensing, manufacture, marketing, and distribution of biopharmaceuticals and related healthcare products.
The company also focuses on psychiatric disorders, diabetes, hepatitis B, HIV/AIDS, and rheumatoid arthritis. Its products are sold to wholesalers, hospitals, retail pharmacies, and government entities. The company operates in a single segment, i.e., discovering, developing, licensing, manufacturing, marketing, distributing, and selling innovative medicines that help patients with serious diseases.
BMS operates R&D facilities in the U.S., Belgium, England, France, and Japan. Manufacturing facilities are in Puerto Rico, the U.S., France, Italy, Ireland, Japan, Mexico, and China. Bristol Myers Squibb’s Genome Biology and Emerging Technologies group evaluates and develops emerging genomic-engineering technologies for the drug discovery workflow.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Growth Portfolio : Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Breyanzi, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Augtyro, Cobenfy, Other Growth Portfolio
- Legacy Portfolio : Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane, Other Legacy products.
Applications/End User Industries
- Oncology
- Innovative Treatments
- Cancer
- Immunotherapy
- Therapies
- Cardiovascular Diseases
- Immunological Disorders
- Fibrotic Diseases
- Melanoma
- Renal Cell Carcinoma
- Atrial Fibrillation
- Pulmonary Embolism
- Lymphoma
- Rheumatoid Arthritis
- Myelodysplastic
- Schizophrenia
